Medindia

X

Paloma Pharmaceuticals Receives Approval to Enter Phase I Clinical Trials

Friday, February 5, 2010 Research News J E 4
Advertisement
- IND Accepted by FDA to Initiate Intravitreal and Subconjunctival Administration of Palomid 529 in Age-Related Macular Degeneration Patients -

David Sherris  

617-407-6314

dsherris@palomapharma.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Ascension Health and American Well to Bring Online...
S
First Fractional Laser FDA Cleared for Striae